Stuart Lutzker
CIK 2009257 · View on SEC EDGAR ↗
First SEC filing: Jan. 25, 2024 · Latest: Jan. 25, 2024
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | AVBP | A | 150,000 | — | — | 150,000 Direct | — | Acquired | (price as of 2026-08-20) |
| Feb. 3, 2025 | AVBP | A | 120,000 | — | — | 120,000 Direct | — | Acquired | (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | AVBP | Stock Option (right to buy) | Common Stock (150,000) | $22.67 | Feb. 2, 2036 | 150,000 | Acquired |
| Feb. 3, 2025 | AVBP | Stock Option (right to buy) | Common Stock (120,000) | $27.56 | Feb. 3, 2035 | 120,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 6 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Jan. 25, 2024 | AVBP | Common Stock | — | Direct |
| Jan. 25, 2024 | AVBP | Stock Option (right to buy)→ Common Stock | — | Direct |
| Jan. 25, 2024 | AVBP | Stock Option (right to buy)→ Common Stock | — | Direct |
| Jan. 25, 2024 | AVBP | Stock Option (right to buy)→ Common Stock | — | Direct |
| Jan. 25, 2024 | AVBP | Stock Option (right to buy)→ Common Stock | — | Direct |
| Jan. 25, 2024 | AVBP | Stock Option (right to buy)→ Common Stock | — | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
AVBP
M.D., Ph.D.............. President, Research and Development| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $476,867 | — | — | $119,326 | $219,359 | — | $13,200 | $828,752 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.